loading...| Preferred Name | Sipuleucel-T | |
| Synonyms |
Sipuleucel-T SIPULEUCEL-T APC8015 Vaccine sipuleucel-t PA2024 (PAP/GM-CSF)-Loaded Dendritic Cell Vaccine sipuleucel-T APC8015 Provenge SipT |
|
| Definitions |
A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. (NCI05) |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1985 |
|
| ALT_DEFINITION |
A drug used to treat prostate cancer that has spread. It is made from immune system cells collected from a patient with prostate cancer. The cells are treated with a protein that is made by combining a protein found on prostate cancer cells with a growth factor. When the cells are injected back into the patient, they may stimulate T cells to kill prostate cancer cells. Provenge is a type of vaccine and a type of cellular adoptive immunotherapy. |
|
| CAS_Registry |
917381-47-6 |
|
| code |
C1985 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C192234 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc OORO |
|
| DEFINITION |
A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. (NCI05) |
|
| Display_Name |
Sipuleucel-T |
|
| FDA_UNII_Code |
8Q622VDR18 |
|
| FULL_SYN |
Sipuleucel-T SIPULEUCEL-T APC8015 Vaccine sipuleucel-t PA2024 (PAP/GM-CSF)-Loaded Dendritic Cell Vaccine sipuleucel-T APC8015 Provenge SipT |
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Sipuleucel-T |
|
| Legacy Concept Name |
APC8015_Vaccine |
|
| Maps_To |
Sipuleucel-T |
|
| NCI_Drug_Dictionary_ID |
38038 |
|
| NSC Number |
720270 |
|
| PDQ_Closed_Trial_Search_ID |
38038 |
|
| PDQ_Open_Trial_Search_ID |
38038 |
|
| Preferred_Name |
Sipuleucel-T |
|
| prefixIRI |
Thesaurus:C1985 |
|
| Semantic_Type |
Pharmacologic Substance Immunologic Factor Cell |
|
| UMLS_CUI |
C1706668 |
|
| subClassOf |